The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and RFK Jr pushes for FDA approval of BPC 157 peptide Eric Topol, MD posted on the topic LinkedIn Gray Market Peptides: So Much Hype, So Little Data FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn FDA moves toward easing restrictions on certain peptides BioPharma Dive